Amylyx signs avexitide supply deals with Bachem and Polypeptide
Amylyx Pharmaceuticals entered two non-exclusive agreements for long-term avexitide commercial supply. It signed a five-year Manufacturing and Supply Agreement with Bachem starting in 2028 and a separate agreement with Polypeptide, with $30 million upfront to reserve capacity.